Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Cash from Investing Activities: 2023-2025

Historic Cash from Investing Activities for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $2.5 million.

  • NewAmsterdam Pharma Co N.V's Cash from Investing Activities rose 3441.33% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$216.0 million, marking a year-over-year decrease of 32036.01%. This contributed to the annual value of -$62.8 million for FY2024, which is 261766.67% down from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Cash from Investing Activities stood at $2.5 million for Q3 2025, which was up 101.57% from -$159.1 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Cash from Investing Activities registered a high of $2.9 million during Q1 2025, and its lowest value of -$159.1 million during Q2 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Cash from Investing Activities value was -$9,000 (recorded in 2023), while the average stood at -$19.7 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Cash from Investing Activities slumped by 2,072,533.33% in 2024, and later surged by 3,441.33% in 2025.
  • NewAmsterdam Pharma Co N.V's Cash from Investing Activities (Quarterly) stood at -$3,000 in 2023, then plummeted by 2,072,533.33% to -$62.2 million in 2024, then soared by 3,441.33% to $2.5 million in 2025.
  • Its Cash from Investing Activities stands at $2.5 million for Q3 2025, versus -$159.1 million for Q2 2025 and $2.9 million for Q1 2025.